Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Thyroplasty in the previously irradiated neck: A case series and short‐term outcomes
White, James R. , Orbelo, Diana M. , Noel, Daniel B., Pittelko, Rebecca L. , Maragos, Nicolas E., Ekbom, Dale C. , Orbelo, Diana

The Laryngoscope | November 3, 2015 | Volume: 126 | Issue: 8 | Pages: 1849-1853

10.1002/lary.25770 | PMID 26526375 Get It

Objectives/HypothesisExternal beam radiation to the neck is widely considered a contraindication for thyroplasty due to concern for infection and implant extrusion. We present a case series of our experience regarding thyroplasty performed in a previously radiated field.Study DesignRetrospective case study at a tertiary academic referral center.MethodsUsing the institution's clinical notes search tool, records from 1999 through 2014 documenting thyroplasty and radiation were identified and reviewed. Patients who received external beam radiation to the operative field prior to thyroplasty were included. Data including duration of radiation, timing and specifics of thyroplasty, postoperative complications, risk factors, clinical voice outcomes, and length of follow‐up were collected.ResultsFourteen patients met criteria for the study. Of all thyroplasty performed, 11 were Silastic implants, two were Gore‐Tex implants, six had concurrent arytenoid adduction, and one was a midline type II thyroplasty. In terms of risk factors for postoperative complications, two were diabetic, none were active smokers, and one had a splenectomy. All patients were given postoperative antibiotics. The median duration of follow‐up after surgery was 14.2 months. No patients were found to have postoperative complications. Pre‐ and postoperative voice data were assessed. Overall, there was improvement in voice outcomes.ConclusionsThyroplasty may be an option for patients who have previously undergone external beam radiation. Short‐term and intermediate outcomes in our patients showed no postoperative complications, and generally voice or dysphagia improved. Careful selection is still warranted when considering thyroplasty in a previously irradiated neck, and long‐term outcomes need further study.Level of Evidence4 Laryngoscope, 126:1849–1853, 2016
CRISP: Catheterization RISk score for pediatrics: A Report from the Congenital Cardiac Interventional Study Consortium (CCISC)
Nykanen, David, Forbes, Thomas J., Du, Wei , Divekar, Abhay , Reeves, Jaxk, Hagler, Donald J. , Fagan, Thomas E. , Pedra, Carlos A. C., Fleming, Gregory A. , Khan, Danyal , Javois, Alexander J., Gruenstein, Daniel H., Qureshi, Shakeel A. , Moore, Phillip, Wax, David H., Moore, Phillip , Wax, David

Catheterization and Cardiovascular Interventions | November 3, 2015 | Volume: 87 | Issue: 2 | Pages: 302-309

10.1002/ccd.26300 | PMID 26527119 Get It

ObjectivesWe sought to develop a scoring system that predicts the risk of serious adverse events (SAE's) for individual pediatric patients undergoing cardiac catheterization procedures.BackgroundSystematic assessment of risk of SAE in pediatric catheterization can be challenging in view of a wide variation in procedure and patient complexity as well as rapidly evolving technology.MethodsA 10 component scoring system was originally developed based on expert consensus and review of the existing literature. Data from an international multi‐institutional catheterization registry (CCISC) between 2008 and 2013 were used to validate this scoring system. In addition we used multivariate methods to further refine the original risk score to improve its predictive power of SAE's. Results: Univariate analysis confirmed the strong correlation of each of the 10 components of the original risk score with SAE attributed to a pediatric cardiac catheterization (P < 0.001 for all variables). Multivariate analysis resulted in a modified risk score (CRISP) that corresponds to an increase in value of area under a receiver operating characteristic curve (AUC) from 0.715 to 0.741.ConclusionThe CRISP score predicts risk of occurrence of an SAE for individual patients undergoing pediatric cardiac catheterization procedures. © 2015 Wiley Periodicals, Inc.
Age and Its Association with Low Insulin and High Amyloid-β Peptides in Blood
Li, Huajie , Zhu, Haihao , Wallack, Max , Mwamburi, Mkaya, Abdul‐Hay, Samer O., Leissring, Malcolm A. , Qiu, Wei Qiao

Journal of Alzheimer's Disease | November 3, 2015 | Volume: 49 | Issue: 1 | Pages: 129-137

10.3233/jad-150428 | PMID 26444783 Get It

Age is the major risk factor for developing Alzheimer’s disease (AD), and modifying age-related factors may help to delay the onset of the disease. The goal of this study was to investigate the relationship between age and the metabolic factors related to the risk of developing AD. The concentrations of insulin, amylin, and amyloid-β peptide (Aβ) in plasma were measured. We further measured the activity of serum Aβ degradation by using fluorescein- and biotin-labeled Aβ40. Apolipoprotein E4 allele (ApoE4) and cognitive impairment were characterized. Subjects were divided into three age groups: 60–70, 70–80, and ≥80 years old. We found that the older the subjects, the lower the concentration of insulin (p = 0.001) and the higher the concentration of Aβ1-40 (p = 0.004) in plasma. However, age was not associated with the concentration of another pancreatic peptide, amylin, and only marginally with Aβ1-42. These relationships remained in the absence of diabetes, cardiovascular disease, and stroke, and regardless of the presence of ApoE4 and cognitive impairment. Both age and ApoE4 were inversely associated with, while insulin was positively associated with, the activities of Aβ degradation in serum. Our study suggested that low concentration of insulin and high concentration of Aβ40 are aging factors related to the risk of AD.
Walker 256 tumor‐bearing rats demonstrate altered interstitial cells of Cajal. Effects on ICC in the Walker 256 tumor model
Fracaro, Luciane , Frez, Flávia Cristina Vieira , Silva, B. C., Vicentini, Geraldo Emı́lio , Souza, Sara Raquel Garcia de , Martins, Heber Amilcar , Guarnier, Flávia Alessandra , Zanoni, Jacqueline Nelisis , Linden, David R.

Neurogastroenterology & Motility | November 3, 2015 | Volume: 28 | Issue: 1 | Pages: 101-115

10.1111/nmo.12702 | PMID 26526599 Get It

AbstractBackgroundCachexia is a significant problem in patients with cancer. The effect of cancer on interstitial cells of Cajal (ICC) and neurons of the gastrointestinal tract have not been studied previously. Although supplementation with L‐glutamine 2% may have beneficial effects in cancer‐related cachexia, and be protective of ICC in models of oxidative stress such as diabetes, its effects on ICC in cancer have also not been studied.MethodsTwenty‐eight male Wistar rats were divided into four groups: control (C), control supplemented with L‐glutamine (CG), Walker 256 tumor (WT), and Walker 256 tumor supplemented with L‐glutamine (WTG). Rats were implanted with tumor cells or injected with saline in the right flank. After 14 days, the jejunal tissues were collected and processed for immunohistochemical techniques including whole mounts and cryosections and Western blot analysis.Key ResultsTumor‐bearing rats demonstrate reduced numbers of Myenteric ICC and deep muscular plexus ICC and yet increased Ano1 protein expression and enhanced ICC networks. In addition, there is more nNOS protein expressed in tumor‐bearing rats compared to controls. L‐glutamine treatment had a variety of effects on ICC that may be related to the disease state and the interaction of ICC and nNOS neurons. Regardless, L‐glutamine reduced the size of tumors and also tumor‐induced cachexia that was not due to altered food intake.Conclusions & InferencesThere are significant effects on ICC in the Walker 256 tumor model. Although supplementation with L‐glutamine has differential and complex effects of ICC, it reduces tumor size and tumor‐associated cachexia, which supports its beneficial therapeutic role in cancer.
24‐Year‐Old Woman with Recent Onset Back Pain
Spengel, Kenneth C., Aleff, Patrice C. Abell, Rivera, Michael , Wald, John T. , Abell Aleff, Patrice C, Giannini, Caterina

Brain Pathology | November 3, 2015 | Volume: 25 | Issue: 6 | Pages: 786-787

10.1111/bpa.12324 | PMID 26526948 Get It

Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group
Fabian, Carol J. , Meyskens, Frank L. , Bajorin, Dean F. , George, Thomas J. , Jeter, Joanne , Khan, Shakila P. , Tyne, Courtney, William, William N. , Jeter, Joanne M, Khan, Shakila, Tyne, Courtney A, George, Thomas J

Journal of Clinical Oncology | November 3, 2015 | Volume: 34 | Issue: 2 | Pages: 186-193

10.1200/jco.2015.63.5979 | PMID 26527778 Get It

Purpose To assist in determining barriers to an oncology career incorporating cancer prevention, the American Society of Clinical Oncology (ASCO) Cancer Prevention Workforce Pipeline Work Group sponsored surveys of training program directors and oncology fellows. Methods Separate surveys with parallel questions were administered to training program directors at their fall 2013 retreat and to oncology fellows as part of their February 2014 in-training examination survey. Forty-seven (67%) of 70 training directors and 1,306 (80%) of 1,634 oncology fellows taking the in-training examination survey answered questions. Results Training directors estimated that ≤ 10% of fellows starting an academic career or entering private practice would have a career focus in cancer prevention. Only 15% of fellows indicated they would likely be interested in cancer prevention as a career focus, although only 12% thought prevention was unimportant relative to treatment. Top fellow-listed barriers to an academic career were difficulty in obtaining funding and lower compensation. Additional barriers to an academic career with a prevention focus included unclear career model, lack of clinical mentors, lack of clinical training opportunities, and concerns about reimbursement. Conclusion Reluctance to incorporate cancer prevention into an oncology career seems to stem from lack of mentors and exposure during training, unclear career path, and uncertainty regarding reimbursement. Suggested approaches to begin to remedy this problem include: 1) more ASCO-led and other prevention educational resources for fellows, training directors, and practicing oncologists; 2) an increase in funded training and clinical research opportunities, including reintroduction of the R25T award; 3) an increase in the prevention content of accrediting examinations for clinical oncologists; and 4) interaction with policymakers to broaden the scope and depth of reimbursement for prevention counseling and intervention services.
TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes
Varghese, Ron T. , Miles, John M., Piccinini, Francesca, Man, Chiara Dalla , Bailey, Kent R. , Rizza, Robert A., Shah, Mithun V , Miles, John M., Cobelli, Claudio , Vella, Adrian , Dalla Man, Chiara

Diabetes | November 3, 2015 | Volume: 65 | Issue: 2 | Pages: 371-380

10.2337/db15-1233 | PMID 26525881 Get It

The diabetes-associated allele in TCF7L2 increases the rate of conversion to diabetes; however, the mechanism by which this occurs remains elusive. We hypothesized that the diabetes-associated allele in this locus (rs7903146) impairs insulin secretion and that this defect would be exacerbated by acute free fatty acid (FFA)–induced insulin resistance. We studied 120 individuals of whom one-half were homozygous for the diabetes-associated allele TT at rs7903146 and one-half were homozygous for the protective allele CC. After a screening examination during which glucose tolerance status was determined, subjects were studied on two occasions in random order while undergoing an oral challenge. During one study day, FFA was elevated by infusion of Intralipid plus heparin. On the other study day, subjects received the same amount of glycerol as present in the Intralipid infusion. β-Cell responsivity indices were estimated with the oral C-peptide minimal model. We report that β-cell responsivity was slightly impaired in the TT genotype group. Moreover, the hyperbolic relationship between insulin secretion and β-cell responsivity differed significantly between genotypes. Subjects also exhibited impaired suppression of glucagon after an oral challenge. These data imply that a genetic variant harbored within the TCF7L2 locus impairs glucose tolerance through effects on glucagon as well as on insulin secretion.
A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution
Walsh, Kyle M. , Smith, Adam J. de , Hansen, Helen M. , Smirnov, Ivan, Gonseth, Semira , Endicott, Alyson , Xiao, Jianqiao, Rice, Terri, Fu, Cecilia, McCoy, Lucie , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Wrensch, Margaret , Metayer, Catherine , Wiemels, Joseph L. , Lachance, Daniel Honore , Wiencke, John K. , Ma, Xiaomei

Cancer Research | November 2, 2015 | Volume: 75 | Issue: 22 | Pages: 4884-4894

10.1158/0008-5472.can-15-1105 | PMID 26527286 Get It

Abstract Genome-wide association studies (GWAS) have identified SNPs in six genes that are associated with childhood acute lymphoblastic leukemia (ALL). A lead SNP was found to occur on chromosome 9p21.3, a region that is deleted in 30% of childhood ALLs, suggesting the presence of causal polymorphisms linked to ALL risk. We used SNP genotyping and imputation-based fine-mapping of a multiethnic ALL case–control population (Ncases = 1,464, Ncontrols = 3,279) to identify variants of large effect within 9p21.3. We identified a CDKN2A missense variant (rs3731249) with 2% allele frequency in controls that confers three-fold increased risk of ALL in children of European ancestry (OR, 2.99; P = 1.51 × 10−9) and Hispanic children (OR, 2.77; P = 3.78 × 10−4). Moreover, of 17 patients whose tumors displayed allelic imbalance at CDKN2A, 14 preferentially retained the risk allele and lost the protective allele (PBinomial = 0.006), suggesting that the risk allele provides a selective advantage during tumor growth. Notably, the CDKN2A variant was not significantly associated with melanoma, glioblastoma, or pancreatic cancer risk, implying that this polymorphism specifically confers ALL risk but not general cancer risk. Taken together, our findings demonstrate that coding polymorphisms of large effect can underlie GWAS “hits” and that inherited polymorphisms may undergo directional selection during clonal expansion of tumors. Cancer Res; 75(22); 4884–94. ©2015 AACR.
JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age
Xu, Ming , Tchkonia, Tamar , Ding, Husheng, Ogrodnik, Mikołaj , Lubbers, Ellen R. , Pirtskhalava, Tamar , White, Thomas A. , Johnson, Kurt O. , Mezera, Vojtěch , Giorgadze, Nino, Jensen, Michael D. , LeBrasseur, Nathan K. , Kirkland, James L. , Tchkonia, Tamara, Stout, Michael B, Stout, Michael B , Xu, Ming , Tchkonia, T , LeBrasseur, Nathan K

Proceedings of the National Academy of Sciences | November 2, 2015 | Volume: 112 | Issue: 46 | Pages: No page available

10.1073/pnas.1515386112 | PMID 26578790 Get It

Significance A hallmark of aging is chronic sterile inflammation, which is closely associated with frailty and age-related diseases. We found that senescent fat progenitor cells accumulate in adipose tissue with aging and acquire a senescence-associated secretory phenotype (SASP), with increased production of proinflammatory cytokines compared with nonsenescent cells. These cells provoked inflammation in adipose tissue and induced macrophage migration. The JAK pathway is activated in adipose tissue with aging, and the SASP can be suppressed by inhibiting the JAK pathway in senescent cells. JAK1/2 inhibitors reduced inflammation and alleviated frailty in aged mice. One possible mechanism contributing to reduced frailty is SASP inhibition. Our study points to the JAK pathway as a potential target for countering age-related dysfunction.
Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease
Palmer, Jeanne , Chai, Xiaoyu , Pidala, Joseph, Inamoto, Yoshihiro , Storer, Barry E. , Pusic, Iskra , Arora, Mukta , Pavletic, Steven Z. , Lee, Stephanie J. , Martin, Paul J. , Flowers, Mary E.D. , Lee, Stephanie J

Blood | November 2, 2015 | Volume: 127 | Issue: 1 | Pages: 160-166

10.1182/blood-2015-08-662874 | PMID 26527676 Get It

Key Points Survival of chronic GVHD patients was predicted by clinician-assessed response and changes in patient-reported outcomes. FFS was predicted by clinician-assessed response, changes in patient-reported outcomes, and the 2014 NIH response criteria.